How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,514 results for

Medications Associated with Weight Gain

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

, Los Angeles Los Angeles, CA Nancy Lane, M.D. Director and Distinguished Professor Center for Musculoskeletal Health and Department of Internal Medicine University of California at Davis, School of Medicine Sacramento, California Jasvinder Singh, M.D., M.P.H. Division of Rheumatology University of Alabama Birmingham, AL vii Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Structured Abstract Objective. To summarize the effects of long-term (...) drug continuation versus discontinuation ES-14 Table 1. U.S. FDA approved drugs used for osteoporosis treatment and prevention 3 Table 2. PICOTS 7 Table 3. Harms evaluated for possible association with long-term osteoporosis drug therapy 11 Table 4. Study inclusion criteria 14 Table 5. Eligible publications that compared long-term osteoporosis drug use versus control or osteoporosis drug continuation versus discontinuation (placebo drug holiday) and reported on risk of incident fractures

2019 Effective Health Care Program (AHRQ)

2. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

2018 Effective Health Care Program (AHRQ)

3. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

, and weight gain may also occur with intensive insulin therapy. Phase II-IV clinical trials have investigated the use of glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium glucose cotransporter-2 (SGLT-2) inhibitors, and dual sodium glucose transporter-1 and sodium glucose transporter-2 (SGLT-1/SGLT-2) inhibitors as adjunctive therapy with insulin for adult patients with T1D. Available data suggest that these drugs may reduce A1C by 0.1 to 0.6% and total daily (...) than 60,000 new cases yearly. 8 The proportion of diabetic patients with T1D is approximately 10%. 3 Insulin is the mainstay of treatment for T1D. 10 Intensive glucose control has been associated with significant decreases in complications in T1D patients. 11 However, in some cases, it may be difficult for patients to reach target A1C levels on insulin monotherapy. 11 Some patients may also experience hypoglycemia, excessive glucose fluctuations, and weight gain with intensive insulin therapy. 2,11

2018 CADTH - Issues in Emerging Health Technologies

4. New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report

that the efficacy of treatments is similar across drug classes, CDEC identified the values of safety and the efficient use of health care resources as particularly important in making its recommendation for a second-line agent for the treatment of adults with type 2 diabetes. In considering the patients’ perspectives, CDEC noted patients’ concerns about the risk of weight gain and hypoglycemia that can be associated with some diabetes treatments, including sulfonylureas. CDEC noted that patients prefer (...) these limitations, the NMA conducted using results from 84 trials was robust, as efficacy and safety outcomes analyzed were consistent with direct pairwise comparisons. CDEC noted that the clinical trial data suggest that, among all patients with diabetes, clinically meaningful hypoglycemic events are rare across all drug classes, with low absolute rates of severe hypoglycemia reported. Weight gain associated with treatment involving sulfonylureas is relatively small (i.e., approximately 2 kg). CDEC reviewed

2017 CADTH - Plasma Products

5. New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report

that the efficacy of treatments is similar across drug classes, CDEC identified the values of safety and the efficient use of health care resources as particularly important in making its recommendation for a second-line agent for the treatment of adults with type 2 diabetes. In considering the patients’ perspectives, CDEC noted patients’ concerns about the risk of weight gain and hypoglycemia that can be associated with some diabetes treatments, including sulfonylureas. CDEC noted that patients prefer (...) these limitations, the NMA conducted using results from 84 trials was robust, as efficacy and safety outcomes analyzed were consistent with direct pairwise comparisons. CDEC noted that the clinical trial data suggest that, among all patients with diabetes, clinically meaningful hypoglycemic events are rare across all drug classes, with low absolute rates of severe hypoglycemia reported. Weight gain associated with treatment involving sulfonylureas is relatively small (i.e., approximately 2 kg). CDEC reviewed

2017 CADTH - Plasma Products

6. Investigating the link between drug-naive first episode psychoses (FEPs), weight gain abnormalities and brain structural damages: Relevance and implications for therapy. (Abstract)

Investigating the link between drug-naive first episode psychoses (FEPs), weight gain abnormalities and brain structural damages: Relevance and implications for therapy. Evidence suggests that obesity and overweight may be associated with severe brain structural abnormalities and poor cognitive and functional outcomes in the general population. Despite these observations and the high prevalence of weight gain abnormalities in patients with psychosis spectrum disorders (PSDs), no studies have (...) investigated the impact that these metabolic disturbances may have on brain structures and development in the earliest stages of PSDs. In the present review we shed light on the association between weight gain and brain structural abnormalities that may affect the course of illness in drug-naïve FEPs. Given the lack of studies directly investigating this issue, we firstly identified and critically evaluated the literature assessing weight gain abnormalities and gray or white matter (GM, WM) volumes (either

2017 Progress in neuro-psychopharmacology & biological psychiatry

7. Functional Family Therapy (FFT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Full Text available with Trip Pro

version of this article with your friends and colleagues. Copy URL Share a link Share on 1 The terms ‘use’, ‘abuse’ and ‘dependence’ are often used interchangeably and refer to an addiction stage of non‐medical drug usage. of the kind that persists beyond the experimentation phase is a severe problem worldwide ( ). Abuse of non‐opioid drugs such as cannabis, amphetamine and cocaine is strongly associated with a broad range of negative health implications such as traffic accidents, sexually transmitted (...) ‐analytical study, synthesized findings from 17 studies evaluating outpatient treatments for substance‐abusing youth, including several therapy models, among them FFT, other family therapy approaches, group CBT, individual CBT and minimal treatment conditions. found that the effect size associated with reductions in drug abuse was significantly larger for family therapy relative to the minimal treatment condition, but the meta‐analysis did not establish one of the treatment approaches as clearly superior

2015 Campbell Collaboration

8. Family Behavior Therapy (FBT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Full Text available with Trip Pro

medical drug usage. that persists beyond curious experimentation is a severe problem worldwide (United Nations Office of Drugs and Crime . Use of non‐opioid drugs such as cannabis, amphetamine and cocaine is strongly associated with a range of health and social problems, including delinquency, poor scholastic attainment, fatal automobile accidents, suicide and other individual and public calamities ( ; ; ; Office of National Drug Control Policy ; ). More than 20 million of the 12 to 25 year‐olds (...) that can include up to 20 treatment sessions of 1‐2 hours. Duration ranges from 6‐12 months. Delivery is flexible and the intervention can be delivered in an office‐based setting or in the family home ( ). 1.3 HOW THE INTERVENTION MIGHT WORK FBT has two primary objectives: 1) to reduce the young person's drug use, and 2) to change behaviors associated with drug use in the young person and their family. The intervention aims at engaging young people and their families in therapy, improving family

2015 Campbell Collaboration

9. Cognitive?Behavioural Therapies for Young People in Outpatient Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

treatment interventions that are developmentally appropriate for this population ( ; , ). Cognitive‐Behavioural Therapy (CBT) interventions include a variety of such practical elements. As a structured yet flexible, individualized and multicomponent intervention, CBT is adaptable and can be tailored to deal with the challenges associated with specific substances and the individual needs of young people. The focus of this review is on young people enrolled in treatment for drug use, regardless of how (...) stressors ( ; ). CBT aims to address the learned association between drug‐related cues or stimuli and drug use by understanding and changing undesirable cognitive and behavioural patterns ( ; ). CBT combines behavioural and cognitive therapy; while behavioural therapy mainly focuses on external settings and observable behaviour, cognitive therapy is concerned with internal cognitive processes. Behavioural therapy Behavioural therapy was developed from the ideas of classical and operant conditioning

2015 Campbell Collaboration

10. Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non?opioid Drug Abuse: A Systematic Review Full Text available with Trip Pro

Family Therapy (BSFT) for young people in treatment for illicit non‐opioid drug use . 1.2 DESCRIPTION OF THE INTERVENTION Multidimensional Family Therapy (MDFT) has evolved over the last twenty years and is a manual‐based, family‐oriented treatment designed to eliminate drug abuse and associated problems in young people's lives (Liddle, 1999; ; ). MDFT is one of several family therapy forms that meet the general characteristics of manual‐based family therapies in that it deals with young people (...) Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non?opioid Drug Abuse: A Systematic Review Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non‐opioid Drug Abuse: A Systematic Review - Filges - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Multidimensional Family Therapy (MDFT

2015 Campbell Collaboration

11. Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

this review and refer to an addiction stage of non‐medical drug usage; this definition implies that the term ‘use’ refers to the consumption of drugs beyond experimentation and into addiction. of the kind that persists beyond the experimentation phase is a severe problem worldwide (United Nations Office of Drugs and Crime (UNODC), 2010), and the use of non‐opioid drugs such as cannabis, amphetamines and cocaine is strongly associated with a broad range of health and social problems, including delinquency (...) Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non‐Opioid Drug Use: A Systematic Review - Lindstrøm - 2013 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Brief Strategic Family Therapy (BSFT

2013 Campbell Collaboration

12. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes Full Text available with Trip Pro

classes of non-insulin antidiabetic drugs, given alongside metformin therapy, in patients with type 2 diabetes mellitus not controlled by metformin alone. The authors concluded that all classes of drug were associated with similar glycated haemoglobin A 1c reductions, but differed in their associations with weight gain and risk of hypoglycaemia. These conclusions are likely to be reliable. Authors' objectives To determine the comparative efficacy, risk of weight gain, and hypoglycaemia associated (...) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes Phung OJ, Scholle JM, Talwar M, Coleman CI CRD summary This review assessed different

2010 DARE.

13. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs Full Text available with Trip Pro

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver disease (NAFLD). NASH can progress to hepatic fibrosis, cirrhosis, portal hypertension and primary liver cancer. Therapy is evolving with a substantial number of trials of promising new agents now in progress. In this article however, we will examine data for several older forms of therapy which have been fairly (...) extensively studied over the years: Polyunsaturated Fatty Acid (PUFA) supplements, vitamin E, insulin sensitizing agents with a focus on pioglitazone and statin agents. Early interest in PUFA derived from their potential benefit in cardio-metabolic disease and the close association of NAFLD/NASH with Metabolic Syndrome. Results have been variable although most studies show reduction of liver fat without other major effects and their effects are influenced by concomitant weight loss and underlying genetic

2017 Clinical and molecular hepatology

14. Bone loss with antiepileptic drug therapy: a twin and sibling study. Full Text available with Trip Pro

Bone loss with antiepileptic drug therapy: a twin and sibling study. Changes in areal bone mineral density (aBMD) and other predictors of bone loss were evaluated in 48 same-sex twin/age-matched sibling pairs discordant for antiepileptic drug (AED) use. AED users had reduced BMD at the hip regions. Prolonged AED users had greater aBMD loss, predicting a higher risk of bone fragility.To investigate the longitudinal associations of bone mineral measures with antiepileptic drug (AED) use (...) for age, weight, and height. Predictors of bone loss were evaluated.AED users, compared to non-users, at baseline and follow-up, respectively, had reduced aBMD at the total hip (MWPD% 3.8, 4.4%), femoral neck (4.7, 4.5%), and trochanter regions (4.1, 4.6%) (p < 0.05). For the whole cohort, the annual rate of change in all aBMD/BMC (p > 0.05) regions did not differ within pairs. Nevertheless, EIAED users had greater aBMD loss than non-users (n = 20 pairs) at the total hip (1.7 vs. 0.3%, p = 0.013

2017 Osteoporosis International

15. Medical Nutrition Therapy Program and Eating Behavior Questionnaires on Gestational Weight Gain

hand Medical nutrition therapy (MNT) has been shown to reduce some complications in women with T2DM and GDM. The aim of this project was to assess the association of MNT consultations and eating behavior with GWG in Mexican women with T2DM and GDM. Condition or disease Intervention/treatment Gestational Weight Gain Behavioral: Medical Nutrition Therapy Detailed Description: This cross-sectional study conducted at from 2013 to 2014. Fifty seven patients with T2DM or GDM were invited to participate (...) . The dependent variable was GWG and the main independent variables were MNT and eating behaviors. Data were obtained from medical records or interviews. Multiple linear regression models were used to assess associations. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 57 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Medical Nutrition Therapy Program and Eating Behavior Questionnaires on Gestational Weight Gain

2018 Clinical Trials

16. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai

Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai October 2019 EUnetHTA Joint Action 3 WP4 1 EUnetHTA Joint Action 3 WP4 Version 1.0, 22/10/2019 Relative effectiveness assessment of pharmaceutical technologies USTEKINUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE (...) and Pharmaceutical Benefits Agency (TLV). Relative effectiveness assessment of pharmaceutical technologies. Ustekinumab for the treat- ment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. EUnetHTA Project ID: PTJA07. 2019. PTJA07 - Ustekinumab for active ulcerative colitis October 2019 EUnetHTA Joint Action 3

2020 EUnetHTA

17. Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review

of prescription drug therapy 1 1.2 ICBC prescription medication funding policy 2 1.3 Herbal cannabis and pharmaceutical cannabinoids in clinical medical practice in Canada 2 2.0 An overview of a graduated evidence-informed, ICBC funding model 3 2.1 Funding policy decisions within a graduated, evidence informed ICBC funding model 5 2.2 Pharmaceutical cannabinoid medications for regulatory approved indications (LEVEL 1) 6 2.3 Pharmaceutical cannabinoids for indications without regulatory approval (LEVEL 2) 6 (...) and a doctor’s prescription which, to some extent, it adjudicates as to the appropriateness of diagnosis and the type and volume of drugs prescribed. Decisions regarding funding of herbal cannabis and pharmaceutical cannabinoidss fit within this well established ICBC funding policy framework. 1.3 Herbal cannabis and pharmaceutical cannabinoids in clinical medical practice in Canada The application of scientific medical knowledge of herbal cannabis and pharmaceutical cannabinoid therapy to clinical medical

2020 Therapeutics Letter

18. Influence of Medical Nutrition Therapy and Eating Behavior on Gestational Weight Gain

of Mexico Information provided by (Responsible Party): Hugo Mendieta Zeron, Materno-Perinatal Hospital of the State of Mexico Study Details Study Description Go to Brief Summary: To assess the association of the number of medical nutrition therapy (MNT) consultations and eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) with GWG in women with type 2 diabetes mellitus (T2DM) and gestational diabetes mellitus (GDM). Condition or disease Weight Gain Eating Behavior Detailed (...) Title: Influence of Medical Nutrition Therapy and Eating Behavior on Gestational Weight Gain in Women With Diabetes Actual Study Start Date : November 1, 2013 Actual Primary Completion Date : June 1, 2014 Actual Study Completion Date : November 30, 2014 Resource links provided by the National Library of Medicine related topics: (AHRQ) related information: Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Gestational Weight Gain (GWG). [ Time Frame: 9 months ] GWG

2017 Clinical Trials

19. Pharmaceutical interventions for weight-loss maintenance: no effect from cabergoline (Abstract)

Pharmaceutical interventions for weight-loss maintenance: no effect from cabergoline Weight regain is a major limitation to successful weight maintenance following weight loss. Observational studies suggest that stimulation of dopamine receptors in the central nervous system is associated with weight loss and inhibition of weight gain. Our objective was to test the hypothesis that dopamine agonist treatment would prevent weight regain following acute weight loss in individuals with obesity.We (...) conducted a 2-year double blind randomised controlled trial comparing the effect of a dopamine agonist, cabergoline, with placebo on weight regain in obese individuals who had lost at least 5% of their body weight using an 800 kcal/day commercial meal replacement programme. The primary outcome measure was the difference in mean weight between the treatment and control groups over the 2-year period following randomisation.At 24 months, there was no difference in body weight between cabergoline

2018 EvidenceUpdates

20. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment

weight risk (Roffeei et al., 2014). These genetic factors associated with drug-induced weight gain and its metabolic consequences provide clues as to the underlying mechanisms, and in the future may provide opportu- nities for personalised medicine in the predictive assessment of metabolic risk with antipsychotic drug treatment. Antipsychotic medications and diabetes. One aspect of the metabolic pathology of schizophrenia is a two-fold increase in diabetes. The aetiology of this is complex (...) BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment Journal of Psychopharmacology 1 –32 © The Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881116645254 jop.sagepub.com BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment Stephen J Cooper 1,3

2016 British Association for Psychopharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>